GlassScriptPhysician profile
Nicholas Butler
NPI 1528444809
$9,580.49
in general payments reported to CMS, 2019-2025
31 companies · $2,607 in 2025
The $2,607 reported for 2025 was more than what 87% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $4,553 · 2021: $78.83 · 2022: $96.40 · 2023: $1,219 · 2024: $717 · 2025: $2,607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,290 · Travel and Lodging: $1,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,290.10 |
| Travel and Lodging | $1,253.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Liberty Surgical INC. | $4,409.57 | 2020 | |
| Paragon 28, INC. | $1,321.12 | 2023-2025 | Portfolio, Bun-Yo-Matic, Precision Mis Bunion |
| Stryker Corporation | $863.61 | 2019-2025 | Actishield, Augment Injectable, 7 X 23mm Citrelock Implant |
| Integra Lifesciences Corporation | $620.75 | 2023-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Treace Medical Concepts, INC. | $617.94 | 2023 | |
| Organogenesis INC. | $283.62 | 2019-2025 | Puraply Wound Matrix |
| Smith+Nephew, INC. | $157.72 | 2022-2025 | Collagenase Santyl, Renasys Go V2 Home, Profore Kit Lf Ankle Circ 18-25cm Case 8 |
| Ani Pharmaceuticals, INC. | $132.45 | 2024-2025 | Purified Cortrophin Gel |
| Kerecis Limited | $131.97 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Acell, INC. | $121.49 | 2019 | |
| Averitas Pharma INC. | $108.92 | 2023-2025 | Qutenza |
| Paratek Pharmaceuticals, INC. | $106.73 | 2024-2025 | Nuzyra |
| Rock Medical Orthopedics, INC. | $98.87 | 2023 | |
| Mimedx Group, INC. | $95.30 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $60.31 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $47.36 | 2022 | |
| Acera Surgical, INC. | $38.87 | 2025 | Restrata Wound Matrix |
| Amgen INC. | $38.51 | 2024-2025 | Krystexxa |
| Orthofix Medical, INC. | $38.14 | 2025 | Physio-Stim |
| Depuy Synthes Sales INC. | $35.63 | 2019 | |
| Zimmer Biomet Holdings, INC. | $34.55 | 2022 | |
| Bioventus LLC | $32.20 | 2023 | Exogen Ultrasound Bone Healing System |
| Abbvie INC. | $31.47 | 2019-2024 | |
| Nevro Corp. | $29.04 | 2023 | Senza |
| Horizon Therapeutics Plc | $28.97 | 2023 | Krystexxa |
| Abbott Laboratories | $23.54 | 2024 | Esprit |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.40 | 2023 | Jublia |
| Axogen | $18.94 | 2024 | Axoguard Nerve Cap, Axoguard Ha+ Nerve Protector, Axoguard Nerve Protector |
| Medtronic, INC. | $15.40 | 2025 | Inceptiv |
| Nexus Medical Technologies LLC | $14.10 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.